Print Page  Close Window


Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Change (%) Stock is Up 0.06 (2.45%)
Jul 25, 2017 12:20 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
07/10/17Orexigen Announces Presentation of Data for OREX-1019 and OREX-1038, Preclinical Candidates for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug AddictionPrinter Friendly Version
05/16/17Orexigen Announces Activities at European Congress on Obesity 2017Printer Friendly Version
05/09/17Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017Printer Friendly Version
05/02/17Orexigen Therapeutics to Provide Business Update at the 2017 Bank of America Merrill Lynch Healthcare ConferencePrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.